News

This is the eighth generic version of the drug to treat insomnia.

Orally dissolving film formulation of riluzole is now available for patients who have difficulty swallowing.

Insurer also moves two approved biosimilars for Remicade, Avsola and Inflectra, to preferred status.

The biggest price increase was a 9.5% rise for Zogenix’s Fintepla (fenfluramine), used to treat seizures associated with Dravet syndrome.

Males, in particular, have a higher risk of high blood pressure if they have obstructive sleep apnea that goes unaddressed.

The single-dose antibiotic with a one-hour infusion is approved to treat MRSA and other skin infections.

MHE Associate Editor, Briana Contreras, spoke with CEO of Inteliquet, a cancer solutions provider that strives to match patients to clinical trials accurately and promptly in healthcare, Marie Lamont. In this episode Marie discusses the challenges that have affected clinical trials and cancer screenings and how to get trials back on track through technology to avoid the wave of undiagnosed patients post-COVID. She also shared how broadening them through diversity can improve trials.

New research and updated treatment guidelines add to knowledge base on this rare blood cancer.

Everyone seems to be gearing up for value-based care, 2.0. It is hard to argue against the goal of moving from “volume to value.” The jabbing and the jostling are about the best way to get there.

Despite an advisory committee recommendation for approval, the FDA did not approve what would have been the first disease-modifying therapy for type 1 diabetes.

According to the American Urological Association, 72.5% of urologists used Advanced Practice Providers in their practice and these healthcare providers performed a variety of procedures such as a cystoscopy (procedure examining bladder lining), which assists in the diagnosis of bladder cancer. Evidence shows patients have demonstrated a growing acceptance of APPs in urology practice settings.

New, extended-release therapy for post-operative pain reduces the need for opioid pain relief.

The Leukemia & Lymphoma Society is providing grants to increase trial enrollment of ethnic and racial minorities.

Sands ,a medical oncologist who specializes in lung cancer, says the false discovery has been misconstruted as a false positive rate. He also makes a case for early detection and new USPSTF as working to correct disparities.

Researchers identified being Black and of the female gender as the strongest predictors of late-stage diagnosis.

With many offices and schools reopening, social distancing rules being eased, and mask requirements being eliminated for the vaccinated, we’re beginning to get a glimpse into Life After COVID. But we’re not out of the woods yet—and we can lay some of the blame at the feet of the U.S. Food and Drug Administration.

Merck will withdraw Keytruda's advanced gastric indication after an FDA panel vote, a drug with supply problems gets a new indication, NDAs for an HIV therapy, and other news.

The move follows an April 29 vote by the FDA Oncology Drugs Advisory Committee.

If the preliminary findings are validated in larger studies, the method could help clinicians determine which patients are candidates for immune checkpoint inhibitor therapy.

Positive findings for resmetirom and icosabutate were presented at the meeting in June.

Patients are being offered $500 to make the switch.

Data presented at the virtual Sleep 2021 meeting by the Annual American Academy of Sleep Medicine suggests treating sleep apnea or obstructive sleep apnea is important for heart health and better prevents chances of COVID-19.

In this week's episode of "Tuning In to the C-Suite" podcast, Managed Healthcare Executive Senior Editor, Peter Wehrwein and Associate Editor, Briana Contreras, spoke with yet another Editorial Advisory Board Member for a segment of the "Meet the Board" series. The two had the pleasure of chatting with Meg Murray, M.P.A., founding CEO of the Association for Community Affiliated Plans, about her journey in healthcare, her organization and were able to look into some of her views about the ACA, equity and racism in healthcare and the Biden Administration’s effects on healthcare.

A recent study finds that the approval of a biosimilar was associated with a change in the trajectory of net prices.

Data from a phase 2/3 study will be presented in July.

COVID-19 forced providers and health plans to hit the brakes on traditional approaches to managing care—and then continue the journey in another vehicle, at a pace that seemed to approach 100 miles per hour.

But there is no benefit for patients receiving chemotherapy.

Direct contracting between employers and providers is rare but could have some genuine advantages for both parties — and for patients. But providers need to prepare and plan if they are going to get into direct contracting.

Kite plans to submit a supplemental BLA based on these findings.